Fig 1: The abundance of immune cell subsets in treated mice over time, as a percentage of total PBMCsC57BL/6 wild-type mice were treated with a single intravenous injection of lentivirus (3.6–4.0 × 106 IU in 200 µL of PBS), to deliver either the 1D3-CD19CAR-GFP CAR, FMC63-CD19CAR, or control (GFP only). N equals eight mice per group and error bars represent the standard deviation (SD) from the mean value reported for each group. T cells, but not other immune cell subsets tested, show a substantial transduced cell population. (A) Representative flowgrams showing increasing GFP-positive T cells in PBMCs of treated mice, over time. The x axis of the flowgrams is CD3 positivity and GFP positivity on the y axis. (B–E). (B) Total T cells versus 1D3-, FMC63-CD19CAR, and GFP-transduced T cells (CD3+, CD90.2+ T cells). (C) Total B cells versus 1D3-, FMC63-CD19CAR, and GFP-transduced B cells (CD20+, CD45R/B220+ B cells). (D) Total macrophage versus 1D3-, FMC63-CD19CAR, and GFP-transduced macrophage (CD11b+ macrophage and other non-T cells). (E) Total NK/NK-T cells versus 1D3-, FMC63-CD19CAR, and GFP-transduced NK/NK-T cells (CD335+ NK/NKT cells). Flow gating strategy outlined in Figure S4 and data in Table S3 and S4.